20 results
Keyword Kanjinti Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Kanjinti
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 16/05/2018,
, Revision: 10, Authorised, Last updated: 24/03/2023
Kanjinti Cancer Neoplasms Gastrointestinal … Kanjinti … EMA/191628/2018 EMEA/H/C/004361 Kanjinti (trastuzumab) An overview … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018
CHMP, Last updated: 23/03/2018Kanjinti … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 November - 1 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 28/11/2022 to 01/12/2022, Last updated: 03/04/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 24-27 October 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/10/2022 to 27/10/2022, Last updated: 31/03/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 May 2023 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 22/05/2023 to 25/05/2023, Last updated: 22/05/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2022 to 10/06/2022, Last updated: 31/03/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 August 2022
Written procedure, from 16/08/2022 to 19/08/2022, Last updated: 04/10/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 November 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/11/2022 to 10/11/2022, Last updated: 10/01/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/05/2023 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 31/05/2023 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2022
PRAC, Last updated: 10/06/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022
PRAC, Last updated: 28/10/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 March 2018
European Medicines Agency, London, UK, from 19/03/2018 to 22/03/2018, Last updated: 31/05/2018 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 November - 1 December 2022
PRAC, Last updated: 02/12/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 April 2018
European Medicines Agency, London, UK, from 23/04/2018 to 26/04/2018, Last updated: 08/06/2018 -
List item
Newsletter archive
Last updated: 20/10/2015and stomach cancer Kanjinti (trastuzumab) biosimilar …
-
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 12/12/2022 to 15/12/2022, Last updated: 06/04/2021 -
List item
Public data from Article 57 database
Last updated: 17/10/2022 -
List item
CHMP: meeting archive 2016-2018
Last updated: 26/02/2020